Production (Stage)
Pharming Group N.V.
PHAR
$11.21
-$0.9534-7.84%
NASDAQ
| 12/31/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | ||
|---|---|---|---|---|---|
| Revenue | 92.67M | 74.09M | 55.59M | 81.22M | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | 92.67M | 74.09M | 55.59M | 81.22M | |
| Cost of Revenue | 12.21M | 7.98M | 8.39M | 7.12M | |
| Gross Profit | 80.46M | 66.11M | 47.20M | 74.10M | |
| SG&A Expenses | 46.56M | 48.55M | 45.34M | 57.28M | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -143.00K | -912.00K | -345.00K | 20.74M | |
| Total Operating Expenses | 80.94M | 77.21M | 71.90M | 96.51M | |
| Operating Income | 11.73M | -3.12M | -16.31M | -15.29M | |
| Income Before Tax | 6.68M | -60.00K | -16.62M | -2.03M | |
| Income Tax Expenses | 3.82M | 1.16M | -4.18M | 1.09M | |
| Earnings from Continuing Operations | 2.86M | -1.22M | -12.45M | -3.12M | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | 2.86M | -1.22M | -12.45M | -3.12M | |
| EBIT | 11.73M | -3.12M | -16.31M | -15.29M | |
| EBITDA | 19.43M | -1.17M | -10.39M | -7.74M | |
| EPS Basic | 0.00 | 0.00 | -0.02 | 0.00 | |
| Normalized Basic EPS | 0.01 | 0.00 | -- | -0.02 | |
| EPS Diluted | 0.00 | 0.00 | -0.02 | 0.00 | |
| Normalized Diluted EPS | 0.01 | 0.00 | -- | -0.02 | |
| Average Basic Shares Outstanding | 740.00M | 688.98M | 655.16M | 675.00M | |
| Average Diluted Shares Outstanding | 740.00M | 688.98M | 655.16M | 675.00M | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |